Bionoid Pharma, Inc.
Other OTCTotal Valuation
Bionoid Pharma, Inc. carries a market capitalization of 1.62M, placing it among publicly traded companies globally. Its enterprise value stands at -258,839.62, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.62M |
| Enterprise Value | -258,839.62 |
Share Statistics
Bionoid Pharma, Inc. currently has 14,910.00 shares outstanding.
| Shares Outstanding | 14,910.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Bionoid Pharma, Inc. maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2.34, indicating conservative leverage, while an interest coverage ratio of -525.22 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.17 |
| Quick Ratio | 0.14 |
| Debt / Equity | -2.34 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | -525.22 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1,842.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3,099.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bionoid Pharma, Inc.'s stock has declined approximately -89.28571% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.28571% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.08 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.04M, while operating income came in at -9.07M.
| Revenue | N/A |
| Gross Profit | -284,355.00 |
| Operating Income | -9.07M |
| Pretax Income | -9.09M |
| Net Income | -9.09M |
| EBITDA | -9.04M |
| EBIT | -9.07M |
| Earnings Per Share (EPS) | -721.57 |
Balance Sheet
Bionoid Pharma, Inc. holds 300,385.00 in cash and equivalents against 34,613.00 in total debt, resulting in a net debt position of -265,772.00. Total book value stands at -20.34M, with working capital of -1.77M providing operational flexibility.
| Cash & Cash Equivalents | 300,385.00 |
| Total Debt | 34,613.00 |
| Net Debt | -265,772.00 |
| Equity (Book Value) | -20.34M |
| Book Value Per Share | -1,613.74 |
| Working Capital | -1.77M |
Cash Flow
Bionoid Pharma, Inc. produced -2.14M in operating cash flow over the past twelve months.
| Operating Cash Flow | -2.14M |
| Capital Expenditures | N/A |
| Free Cash Flow | -2.14M |
| FCF Per Share | -169.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -34,916.06 |
| FCF Yield | -30,865.00 |
Stock Splits
Bionoid Pharma, Inc.'s most recent stock split took place on August 20, 2021 with a 2500:1 split ratio.
| Last Split Date | 8/20/2021 |
| Split Ratio | 2500:1 |
Scores
Bionoid Pharma, Inc. posts an Altman Z-Score of -163.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -163.77 |